Ryoo Hyunsoo, Kang Minyong, Sung Hyun Hwan, Jeon Hwang Gyun, Jeong Byong Chang, Jeon Seong Soo, Lee Hyun Moo, Park Byung Kwan, Seo Seong Il
Department of Urology, VHS Medical Center, Seoul 05368, Korea.
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.
Diagnostics (Basel). 2022 Sep 23;12(10):2292. doi: 10.3390/diagnostics12102292.
This study aimed to compare functional and oncological outcomes between partial nephrectomy (PN) and radiofrequency ablation (RFA) for a small renal mass (SRM, ≤4 cm) in patients with chronic kidney disease (CKD).
Patients with CKD who underwent either PN or RFA for SRM between 2005 and 2019 were included. Patients were stratified into two categories: CKD stage 2 and CKD stage 3 or higher. We performed propensity score matching (PSM) analysis in patients with CKD stage 2 and CKD stage 3 or higher. We compared the functional and oncological outcomes between two groups according to CKD stage before and after PSM.
Among 1332 patients, 1195 patients were CKD stage 2 and 137 patients were CKD stage 3 or higher. After PSM analysis using age, pre-treatment eGFR, and clinical tumor size as matching variables, the PN and RFA groups had 270 and 135 CKD stage 2 patients, respectively, and both had 53 patients each with CKD stage 3 or higher. There were no significant differences in percent change in eGFR at 1 year post-operation between groups in patients with CKD stage 2 and stage 3 or higher. Among all patients with tissue-proven malignancy, the 5-year recurrence-free survival (RFS), cancer-specific survival, and overall survival were significantly higher in the PN group. However, only the 5-year RFS was significantly higher in the PN group after matching.
Mortality is low in patients with SRM, and functional outcomes were not significantly different between the two treatments. RFA could be an alternative treatment modality in patients who are poor candidates for surgery.
本研究旨在比较慢性肾脏病(CKD)患者中,部分肾切除术(PN)与射频消融术(RFA)治疗小肾肿块(SRM,≤4 cm)的功能和肿瘤学结局。
纳入2005年至2019年间因SRM接受PN或RFA治疗的CKD患者。患者分为两类:CKD 2期和CKD 3期及以上。我们对CKD 2期和CKD 3期及以上的患者进行倾向评分匹配(PSM)分析。我们根据PSM前后的CKD分期比较两组之间的功能和肿瘤学结局。
在1332例患者中,1195例为CKD 2期,137例为CKD 3期及以上。使用年龄、治疗前估算肾小球滤过率(eGFR)和临床肿瘤大小作为匹配变量进行PSM分析后,PN组和RFA组分别有270例和135例CKD 2期患者,两组各有53例CKD 3期及以上患者。CKD 2期和3期及以上患者术后1年eGFR变化百分比在两组之间无显著差异。在所有经组织学证实为恶性肿瘤的患者中,PN组的5年无复发生存率(RFS)、癌症特异性生存率和总生存率显著更高。然而,匹配后仅PN组的5年RFS显著更高。
SRM患者死亡率较低,两种治疗方法的功能结局无显著差异。RFA可能是手术不佳候选患者的替代治疗方式。